HC Wainwright reaffirmed their buy rating on shares of BioLineRx (NASDAQ:BLRX – Free Report) in a research report report published on Tuesday morning, Benzinga reports. HC Wainwright currently has a $21.00 price target on the biotechnology company’s stock. HC Wainwright also issued estimates for BioLineRx’s Q1 2024 earnings at ($0.29) EPS, Q2 2024 earnings at […]

Related Keywords

, Renaissance Technologies , Asset Management Corp , Envestnet Asset Management Inc , Atria Wealth Solutions Inc , Biolinerx Ltd , Free Report , Get Free Report , Wealth Solutions , Asset Management , Management Corp , Linerx Ltd , Biolinerx Daily , Biolinerx , Nasdaq Blrx , Blrx , Medical , Reiterated Rating , Hc Wainwright ,